CRISPR Regulatory Updates

On December 15, 2023, Vertex announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the conditional approval of CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)….
By: Goodwin
Previous Story

Updates on Patent Challenges by Biosimilar Manufacturers at the PTAB

Next Story

Biosimilar Deals Updates: Biocon, AstraZeneca